How Will Novel Mechanisms of New and Emerging Treatments Address the Signs and Symptoms of Dry Eye?

Author(s)/Faculty: Stephen C. Pflugfelder, MD; Francis S. Mah, MD
Release Date: 9/13/2021Expiration Date: 9/12/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.5
Content Type: LectureProvider:
Dry eye disease (DED) is highly prevalent but frequently underdiagnosed and undertreated. An estimated 5% to 15% of Americans have DED, but the actual figure may be higher, as DED is often underdiagnosed. Dry eye disease has a significant impact on work and other activities, and recent years have seen a growing understanding of the deleterious effects that DED and other ocular surface diseases can have on ocular surgery. With increasing understanding of the extent and impact of DED, there is a growing number of emerging treatment options. Clinicians must recognize the patients who are at risk for developing significant disease and which of the available therapies are best suited to their needs. In this activity, expert faculty discuss the burden and risk factors of DED and the currently available therapies. They also will explore the mechanisms of action and available clinical data supporting the use of novel emerging therapies under investigation for treatment of DED.